Shares of BeyondSpring (NASDAQ:BYSI) stock are taking off on Wednesday following an important update regarding the firm’s lung cancer treatment. Source: CI Photos / Shutterstock.com The pharmaceutical company announced that its drug plinabulin met the primary and key secondary endpoints during a registrational trial. According to the release, plinabulin “is a first-in-class, selective immunomodulating microtubule-binding…